Literature DB >> 17142321

Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.

Dun Zhou1, Rajneesh Srivastava, Stefan Nessler, Verena Grummel, Norbert Sommer, Wolfgang Brück, Hans-Peter Hartung, Christine Stadelmann, Bernhard Hemmer.   

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Although the cause of MS is still uncertain, many findings point toward an ongoing autoimmune response to myelin antigens. Because of its location on the outer surface of the myelin sheath and its pathogenicity in the experimental autoimmune encephalomyelitis model, myelin oligodendrocyte glycoprotein (MOG) is one of the potential disease-causing self antigens in MS. However, the role of MOG in the pathogenesis of MS has remained controversial. In this study we addressed the occurrence of autoantibodies to native MOG and its implication for demyelination and axonal loss in MS. We applied a high-sensitivity bioassay, which allowed detecting autoantibodies that bind to the extracellular part of native MOG. Antibodies, mostly IgG, were found in sera that bound with high affinity to strictly conformational epitopes of the extracellular domain of MOG. IgG but not IgM antibody titers to native MOG were significantly higher in MS patients compared with different control groups with the highest prevalence in primary progressive MS patients. Serum autoantibodies to native MOG induced death of MOG-expressing target cells in vitro. Serum from MS patients with high anti-MOG antibody titers stained white matter myelin in rat brain and enhanced demyelination and axonal damage when transferred to autoimmune encephalomyelitis animals. Overall these findings suggest a pathogenic antibody response to native MOG in a subgroup of MS patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142321      PMCID: PMC1748176          DOI: 10.1073/pnas.0607242103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Multiple sclerosis: a two-stage disease.

Authors:  L Steinman
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

Review 2.  New concepts in the immunopathogenesis of multiple sclerosis.

Authors:  Bernhard Hemmer; Juan J Archelos; Hans-Peter Hartung
Journal:  Nat Rev Neurosci       Date:  2002-04       Impact factor: 34.870

3.  Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Authors:  M Reindl; C Linington; U Brehm; R Egg; E Dilitz; F Deisenhammer; W Poewe; T Berger
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

Review 4.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

Review 5.  T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  A Iglesias; J Bauer; T Litzenburger; A Schubart; C Linington
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

6.  A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody.

Authors:  C Linnington; M Webb; P L Woodhams
Journal:  J Neuroimmunol       Date:  1984 Sep-Oct       Impact factor: 3.478

7.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.

Authors:  Thomas Berger; Paul Rubner; Franz Schautzer; Robert Egg; Hanno Ulmer; Irmgard Mayringer; Erika Dilitz; Florian Deisenhammer; Markus Reindl
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

8.  Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.

Authors:  V Lampasona; D Franciotta; R Furlan; S Zanaboni; R Fazio; E Bonifacio; G Comi; G Martino
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

Review 9.  Unravelling the pathogenesis of myasthenia gravis.

Authors:  Angela Vincent
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

10.  Characterization of an established human malignant glioma cell line: LN-18.

Authors:  A C Diserens; N de Tribolet; A Martin-Achard; A C Gaide; J F Schnegg; S Carrel
Journal:  Acta Neuropathol       Date:  1981       Impact factor: 17.088

View more
  80 in total

1.  Antigen microarrays identify CNS-produced autoantibodies in RRMS.

Authors:  F J Quintana; M F Farez; G Izquierdo; M Lucas; I R Cohen; H L Weiner
Journal:  Neurology       Date:  2012-01-18       Impact factor: 9.910

Review 2.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

3.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

Review 4.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

5.  [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].

Authors:  R Gold; P Rieckmann
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

Review 6.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

7.  Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Authors:  Yoh Matsumoto; Il-Kwon Park; Keiko Hiraki; Shin Ohtani; Kuniko Kohyama
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

8.  Apoptotic retinal ganglion cell death in an autoimmune glaucoma model is accompanied by antibody depositions.

Authors:  Stephanie C Joachim; Christine Mondon; Oliver W Gramlich; Franz H Grus; H Burkhard Dick
Journal:  J Mol Neurosci       Date:  2013-10-03       Impact factor: 3.444

Review 9.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

10.  Models of autoimmune demyelination in the central nervous system: on the way to translational medicine.

Authors:  Ralf A Linker; De-Hyung Lee
Journal:  Exp Transl Stroke Med       Date:  2009-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.